(secondQuint)Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy.

 The investigators will carry out a prospective study in patients with PDR and prior complete laser treatment who presented with new dense VH.

 All eyes will be treated with intravitreal injection of bevacizumab (1.

25 mg).

 Complete ophthalmic examination and/or ocular ultrasonography will be performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection.

 Re-injection will be done in non-clearing and recurrent VH.

.

 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy@highlight

To evaluate the efficacy of intravitreal bevacizumab injections for treatment of proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after previous full panretinal photocoagulation (PRP).

